Home
About
- Overview
- Team
- Investors
Science
Pipeline
Partners
News & Events
Contact
Menu Menu

A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

8 September 2025

Biopharma Dive

https://www.nrgtherapeutics.com/wp-content/uploads/2026/08/Neil_Miller_CEO_NRG_Therapeutics_-_in_lab.webp 900 1600 Webadm https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png Webadm2025-09-08 08:04:132026-08-14 13:52:49A UK biotech takes aim at Parkinson’s, ALS by drugging mitochondria

© NRG Therapeutics

Terms & Conditions
Privacy Policy

UK’s NRG Powers Up With £50m For Promising Mitochondrial Therapy

NRG raises $67M to test mitochondrial pore inhibitor in ALS